CCL28 Antibody

What is CCL28 and why is it significant in immunological research?

CCL28 is a CC chemokine involved in host immunity through interactions with chemokine receptors CCR10 and CCR3. It displays dual functionality in immune responses: antimicrobial activity against gram-positive bacteria (e.g., Streptococcus mutans, Staphylococcus aureus), gram-negative bacteria (e.g., Pseudomonas aeruginosa, Klebsiella pneumoniae), and fungi (e.g., Candida albicans), while also orchestrating the trafficking and functioning of lymphocytes at mucosal surfaces . This dual role positions CCL28 as a unique bridge between innate and adaptive immunity, making it a significant target for immunological research. CCL28 is highly expressed in epithelium and mucosal secretions such as milk and saliva, providing constitutive innate immune defense against various pathogens .

What are the primary functional domains of CCL28 that antibodies might target?

CCL28 consists of 108 amino acids with distinct functional domains that antibodies may target. The holoprotein is necessary for full antimicrobial activity, with the C-terminal region being particularly important. Research has shown that removal of 24 C-terminal amino acids results in almost complete loss of antimicrobial activity . The region encompassing amino acids 85-89 is vital, with positively charged amino acids (K or R) in the first two positions being strongly conserved across species from rodents to primates and ruminants . Additionally, CCL28 contains the canonical structure of CC chemokines with three anti-parallel β-sheets followed by a C-terminal α-helix, though interestingly, antimicrobial activity does not appear to depend on the disulfide bonding that is crucial for receptor binding .

How do CCL28 expression patterns differ across tissue types?

CCL28 is expressed in various mucosal tissues but with distinct patterns. The highest expression levels are found in salivary glands, where deregulation correlates with salivary gland tumors, Hodgkin's disease, and Sjögren's syndrome . In mammary glands, CCL28 is specifically expressed at the onset of lactation, paralleling the migration of IgA antibody-secreting cells (ASCs) into these glands . CCL28 is also expressed in lung tissue, where it plays a role in neutrophil accumulation during infection, as demonstrated in models of Acinetobacter baumannii pneumonia . When selecting antibodies for specific tissue studies, researchers should consider these differential expression patterns and validate antibody performance in the target tissue type.

How can CCL28 antibodies be used to investigate mucosal immunity?

CCL28 antibodies are valuable tools for studying mucosal immunity because of CCL28's critical role in the homing of IgA-producing cells to mucosal sites. For effective implementation, researchers should:

• Use neutralizing antibodies to block CCL28 function: Anti-CCL28 antibodies can prevent the migration of IgA ASCs into mammary glands, demonstrating CCL28's regulatory role in IgA ASC migration . This approach can be applied to other mucosal sites to study similar mechanisms.

• Employ tissue-specific immunohistochemistry or immunofluorescence with anti-CCL28 antibodies to map expression patterns across different mucosal tissues and correlate with IgA-producing cell distribution.

• Utilize flow cytometry with anti-CCL28 receptor antibodies (anti-CCR10, anti-CCR3) to identify responsive cell populations in mucosal tissues.

• Apply ELISA or multiplex assays with CCL28 antibodies to quantify CCL28 levels in mucosal secretions such as milk, saliva, and bronchoalveolar lavage fluid.

This comprehensive approach can reveal how CCL28 contributes to mucosal barrier function in various contexts, including infection and inflammation .

What are the optimal methodologies for detecting CCL28 in neutrophil-related studies?

Recent research has revealed CCL28's unexpected role in modulating neutrophil responses. To effectively study this relationship, researchers should:

• Use flow cytometry with anti-CCR3 antibodies to detect receptor expression on neutrophils, particularly after stimulation with proinflammatory molecules (GM-CSF + IFNγ + TNFɑ) which boost CCR3 surface expression .

• Employ immunofluorescence with anti-Ly6G (neutrophil marker) and anti-CCL28 antibodies to quantify neutrophil accumulation in tissues following infection, as demonstrated in models of Salmonella and Acinetobacter infection .

• Measure neutrophil effector functions after CCL28 stimulation:

  • Bacterial killing assays (showing ~40% clearance with CCL28 stimulation vs. ~10% with unstimulated neutrophils against Salmonella)

  • ROS production assays

  • NET formation assays

• Validate findings using neutrophils from CCL28-deficient mice (Ccl28-/-) compared to wild-type counterparts, particularly when examining in vivo neutrophil responses .

These approaches can help elucidate how CCL28 influences neutrophil antimicrobial activity and inflammatory potential in different infection models.

How can CCL28 antibodies be used to distinguish between CCR3 and CCR10 signaling pathways?

CCL28 interacts with both CCR3 and CCR10 receptors, potentially leading to different signaling outcomes. To differentiate these pathways:

• Use selective blocking antibodies: Apply anti-CCR3 and anti-CCR10 blocking antibodies separately in combination with CCL28 stimulation to determine which receptor mediates specific cellular responses.

• Implement receptor-specific knockdown/knockout approaches alongside CCL28 antibodies to validate receptor dependency.

• Perform co-immunoprecipitation with anti-CCL28 antibodies followed by detection with anti-CCR3 or anti-CCR10 antibodies to assess binding preferences in different cell types.

• Utilize receptor expression analysis: During homeostasis, CCR10 appears to be the primary receptor for CCL28, while CCR3 may be more important during immunological stress (as in atopic asthma where CCL28 levels increase and enhance accumulation of IgE-secreting plasma cells expressing CCR3) .

This receptor discrimination is particularly important when studying conditions like HIV-1 infection, where there's a positive correlation between mucosal anti-HIV-1 IgA titers and the CCL28-CCR3/CCR10 system .

What controls are essential when using CCL28 antibodies in functional blocking studies?

When designing blocking experiments with anti-CCL28 antibodies, incorporate these essential controls:

• Isotype control antibody: Use matched isotype control antibodies at the same concentration to account for non-specific effects of antibody binding.

• CCL28 receptor antagonists: Compare CCL28 antibody blocking with specific CCR3 and CCR10 antagonists to validate receptor-specific effects.

• Recombinant CCL28 rescue experiments: Attempt to overcome antibody blocking by adding excess recombinant CCL28.

• Genetic validation: When possible, compare antibody blocking results with data from Ccl28-/- mice or cells with CRISPR/Cas9-mediated CCL28 knockdown.

• Dose-response testing: Determine optimal antibody concentrations by performing dose-response experiments (typically ranging from 0.1-10 μg/ml).

• CCL11 controls: For CCR3-mediated effects, include the alternative CCR3 ligand CCL11/eotaxin as a control, which has been shown to affect neutrophil bacterial killing (~25% clearance compared to ~40% with CCL28) .

These controls help distinguish specific CCL28 blockade effects from non-specific antibody effects and validate functional outcomes.

What experimental approaches can optimize CCL28 antibody detection in tissues with variable expression?

CCL28 expression varies across tissues and can be altered during infection or inflammation. To optimize detection:

• Sample preparation considerations:

  • For tissues with high CCL28 expression (salivary glands): Standard fixation protocols are typically sufficient.

  • For tissues with variable expression (lung during infection): Consider shorter fixation times and more sensitive detection methods.

  • For tissues with inducible expression (mammary glands during lactation): Time sampling appropriately to capture expression peaks.

• Signal amplification techniques:

  • Tyramide signal amplification for immunohistochemistry/immunofluorescence

  • Polymer-based detection systems for enhanced sensitivity

  • Proximity ligation assay for detecting low-abundance protein-protein interactions

• Validation approaches:

  • Use tissues from Ccl28-/- mice as negative controls

  • Compare protein detection with mRNA expression by parallel in situ hybridization

  • Validate antibody specificity by western blot showing the expected molecular weight (approximately 12-14 kDa for CCL28)

• Quantification methods:

  • Digital image analysis with appropriate thresholding for variable expression

  • Normalization to housekeeping proteins

  • Consideration of sampling location (e.g., proximal vs. distal lung regions)

These optimization strategies ensure reliable detection across different experimental conditions and tissue types.

How should CCL28 antibodies be validated for specificity in experimental systems?

Rigorous validation is crucial for confident interpretation of CCL28 antibody-based experiments:

• Specificity validation:

  • Western blot demonstrating single band at expected molecular weight

  • Disappearance of signal in Ccl28-/- tissues or cells

  • Pre-absorption with recombinant CCL28 to confirm specific binding

  • Peptide competition assays with CCL28 epitope peptides

• Cross-reactivity assessment:

  • Test against closely related chemokines (particularly CCL27, which shares 31% amino acid identity with CCL28)

  • Validate across species if using in multiple models (human, mouse, etc.)

• Functional validation:

  • Confirm ability to neutralize CCL28-mediated chemotaxis in migration assays

  • Verify inhibition of CCL28-dependent cellular responses

• Reproducibility verification:

  • Test multiple antibody lots

  • Compare results from different antibody clones targeting distinct epitopes

  • Document batch-specific validation data

This comprehensive validation approach ensures that experimental outcomes can be confidently attributed to specific CCL28 detection or inhibition.

How can CCL28 antibodies be used to investigate its dual antimicrobial and chemotactic functions?

The dual functionality of CCL28 presents unique research opportunities using antibody-based approaches:

• Domain-specific antibodies:

  • Develop antibodies targeting the C-terminal region (amino acids 85-108) to specifically inhibit antimicrobial activity

  • Create antibodies against the N-terminal region to potentially disrupt chemotactic function while preserving antimicrobial activity

• Functional separation experiments:

  • Use selective antibodies in bacterial killing assays to determine if antimicrobial activity can be blocked independently of chemotactic functions

  • Implement migration assays with domain-specific antibodies to assess separation of functions

• Structural studies:

  • Employ antibodies for co-crystallization to determine CCL28's structural conformation during different functions

  • Use conformation-specific antibodies to detect structural changes associated with antimicrobial versus chemotactic activities

• In vivo approaches:

  • Administer function-specific antibodies in mucosal infection models to selectively inhibit antimicrobial or chemotactic functions

  • Compare outcomes with broad CCL28 neutralization or Ccl28-/- models

These approaches can help delineate the structural basis for CCL28's dual functionality and determine if these functions can be pharmacologically separated .

What methodologies can assess CCL28's role in neutrophil extracellular trap (NET) formation?

Recent research indicates CCL28 enhances neutrophil effector functions. To investigate its role in NET formation:

• NET visualization and quantification:

  • Immunofluorescence microscopy with antibodies against NET components (citrullinated histones, myeloperoxidase, neutrophil elastase) following CCL28 stimulation

  • Live cell imaging to capture NET formation dynamics in response to CCL28

  • Quantitative analysis of NET area, number, and density using automated image analysis

• Molecular mechanism studies:

  • Inhibitor experiments targeting NADPH oxidase, PAD4, and other NET-formation pathways to determine mechanism of CCL28-induced NET formation

  • Phosphorylation studies of relevant signaling molecules following CCL28 stimulation

  • RNA-seq analysis of neutrophils with and without CCL28 stimulation to identify transcriptional programs

• Functional consequences assessment:

  • Bacterial trapping assays comparing NETs induced by CCL28 versus other stimuli

  • Tissue damage assessment in infection models comparing Ccl28-/- and wild-type mice

  • NET degradation kinetics following CCL28-induced formation

• CCL28 receptor dependency:

  • Compare NET formation in response to CCL28 with and without CCR3/CCR10 blocking antibodies

  • Assess receptor expression on NET-forming neutrophils using flow cytometry

These methodologies can illuminate how CCL28 influences this important neutrophil defense mechanism and its consequences in infection control .

How can researchers use CCL28 antibodies to study its role in various disease models?

CCL28 has been implicated in multiple disease states, and antibody-based approaches can elucidate its contributions:

• Infectious disease models:

  • Use neutralizing CCL28 antibodies in models of Salmonella infection to assess impact on neutrophil recruitment and bacterial clearance

  • Compare with Ccl28-/- mice showing different outcomes in Salmonella gut infection versus Acinetobacter lung infection

• Cancer research applications:

  • Investigate CCL28 expression in tumor microenvironments using immunohistochemistry

  • Block CCL28 function to assess impact on tumor-infiltrating lymphocytes, particularly in salivary gland tumors where CCL28 expression is deregulated

• Autoimmune disease research:

  • Measure CCL28 expression in models of Sjögren's syndrome

  • Apply neutralizing antibodies to determine if blocking CCL28 ameliorates disease progression

• Comparative disease studies:

  • Use standardized antibody-based detection methods across multiple disease models to create a comprehensive profile of CCL28 involvement

Table 1 below summarizes some key disease associations with CCL28 that could be further investigated using antibody-based approaches:

These disease-focused applications can provide insights into CCL28's role in pathogenesis and potential therapeutic targeting .

What are common pitfalls when using CCL28 antibodies and how can they be addressed?

Researchers may encounter several challenges when working with CCL28 antibodies:

• Cross-reactivity issues:

  • Problem: CCL28 shares 31% amino acid identity with CCL27, potentially causing antibody cross-reactivity .

  • Solution: Validate antibody specificity with recombinant CCL27 and CCL28 proteins; use Ccl28-/- tissues as negative controls.

• Variable tissue expression:

  • Problem: CCL28 expression is highly tissue-dependent and can be induced under specific conditions.

  • Solution: Include positive controls known to express CCL28 (e.g., salivary glands); optimize sampling timing for inducible expression.

• Detection sensitivity limitations:

  • Problem: Low constitutive expression in some tissues may challenge detection limits.

  • Solution: Implement signal amplification methods; consider concentrated sampling from secretions (e.g., bronchoalveolar lavage fluid).

• Protein degradation:

  • Problem: CCL28's antimicrobial properties may relate to its structural features that could affect stability in certain buffers.

  • Solution: Optimize sample preparation protocols; include protease inhibitors; test multiple fixation methods for immunohistochemistry.

• Functional neutralization variability:

  • Problem: Incomplete blocking of CCL28 function due to high local concentrations in tissues.

  • Solution: Determine effective antibody concentrations through dose-response studies; consider local administration for tissue-specific blockade.

Addressing these common pitfalls through careful experimental design and appropriate controls ensures more reliable and interpretable results.

How should researchers analyze conflicting data regarding CCL28 function in different experimental systems?

CCL28 studies may yield conflicting results across different experimental systems. For robust analysis:

• Assess experimental context differences:

  • Compare infection models: CCL28 deficiency protects against lethal Acinetobacter pneumonia but impairs control of Salmonella gut infection .

  • Evaluate timing differences: CCL28's role may shift during acute versus chronic phases of immune responses.

• Examine receptor expression variations:

  • Analyze CCR3/CCR10 expression patterns in different experimental systems.

  • Consider receptor regulation: CCR3 surface expression on neutrophils increases after stimulation with proinflammatory cytokines .

• Consider concentration-dependent effects:

  • High CCL28 concentrations (1 μM) show direct antimicrobial activity .

  • Lower concentrations may primarily mediate chemotactic functions.

• Implement parallel methodology approaches:

  • Run side-by-side comparisons using standardized protocols across different systems.

  • Use multiple antibody clones targeting different epitopes to verify findings.

• Integrate genetic and antibody-based approaches:

  • Compare results from antibody neutralization with genetic knockout models.

  • Consider potential developmental compensation in knockout models versus acute blockade with antibodies.

• Statistical analysis considerations:

  • Perform power analyses to ensure adequate sample sizes for detecting biological differences.

  • Consider meta-analysis approaches when combining data from multiple experimental systems.

This systematic approach to conflicting data can reveal context-dependent functions of CCL28 and provide more nuanced understanding of its biological roles.